Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?

References

• Shipp MA, Harrington DP, Anderson JR, . A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Favier O, Heutte N, Stamatoullas-Bastard A, . Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer 2009;115:1680–1691.
   PubMed Web of Science ®Google Scholar
• Jost LM, Kloke O, Stahel RA. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma. Ann Oncol 2005; 16(Suppl. 1):i58–i59.
   PubMed Web of Science ®Google Scholar
• Jost LM, Stahel RA. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. Ann Oncol 2005;16(Suppl. 1):i54–i55.
   PubMed Web of Science ®Google Scholar
• Wang J, Weiss LM, Chang KL, . Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer 2002;94:1522–1531.
   PubMed Web of Science ®Google Scholar
• Vanhelleputte P, Nijs K, Delforge M, Evers G, Vanderschueren S. Pain during bone marrow aspiration: prevalence and prevention. J Pain Symptom Manage 2003;26:860–886.
   PubMed Web of Science ®Google Scholar
• Bain BJ. Morbidity associated with bone marrow aspiration and trephine biopsy – a review of UK data for 2004. Haematologica 2005;91:1295–1296.
   Google Scholar
• Bain BJ. Bone marrow biopsy morbidity:review of 2003. J Clin Pathol 2005;58:406–408.
   PubMed Web of Science ®Google Scholar
• Morley NJ, Makris M. Bone marrow biopsy related hemorrhage and low molecular weight heparin. Br J Haematol 2003;123:562.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Adult non-Hodgkin lymphoma treatment [internet]. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/healthprofessional
   Google Scholar
• National Cancer Institute. Adult Hodgkin lymphoma treatment [internet]. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/adult-hodgkins/healthprofessional
   Google Scholar
• Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721–728.
   PubMedGoogle Scholar
• Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 2007;34:60–67.
   PubMed Web of Science ®Google Scholar
• Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S–150S.
   PubMed Web of Science ®Google Scholar
• NCCN Task Force. Clinical utility of PET in variety of tumor types. NCCN guidelines. J Natl Comp Cancer Network 2009;7(Suppl. 2): S1–S24.
   Google Scholar
• Carr R, Barrington SF, Madan B, . Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340–3346.
   PubMed Web of Science ®Google Scholar
• Moog F, Bangerter M, Kotzerke J, Guhdmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603–609.
   PubMed Web of Science ®Google Scholar
• Macintyre EA, Vaughan Hudson B, Linch DC, . The value of staging bone marrow trephine biopsy in Hodgkin's disease. Eur J Haematol 1987;39:66–70.
   PubMed Web of Science ®Google Scholar
• Foucar K, McKenna RW, Frizzera G. Bone marrow and blood involvement by lymphoma in relationship to the Lukes-Collins classification. Cancer 1982;49:888–897.
   PubMed Web of Science ®Google Scholar
• Conlan MG, Bast, M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990;8:1163–1172.
   PubMed Web of Science ®Google Scholar
• Cerci JJ, Pracchia LF, Soares J Jr, Linardi CdaC, Meneghetti JC, Buccheri V. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of Hodgkin lymphoma: a single center experience in Brazil. Clinics (Sao Paulo) 2009;64:491–498.
   PubMed Web of Science ®Google Scholar
• Naumann R, Beuthien-Baumann B, Reiss A, . Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004;90:620–625.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kletter K, Becherer A. 18F-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003;64:336–340.
   PubMed Web of Science ®Google Scholar
• Montravers F, McNamara D, Landman-Parker J, . [18F] FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002;29:1155–1165.
   PubMed Web of Science ®Google Scholar
• Buchmann I, Reinhardt M, Elsner K, . 2-(Fluorine-18)fluoro-2-deoxy-glucose positron emission tomography in the detection and staging of malignant lymphoma: a bicenter trial. Cancer 2001;91: 889–899.
   PubMed Web of Science ®Google Scholar
• Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000;11:1273–1279.
   PubMed Web of Science ®Google Scholar
• Fuster D, Chiang S, Andreadis C, . Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun 2006;27: 11–15.
   PubMed Web of Science ®Google Scholar
• Paone G, Itti E, Haioun C, . Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging 2009;36: 745–750.
   PubMed Web of Science ®Google Scholar
• Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958–963.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Vitolo U, Nassi L, . Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 2007;86:897–903.
   PubMed Web of Science ®Google Scholar
• Pelosi E, Penna D, Deandreis D, . FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 2008;52:9–16.
   PubMed Web of Science ®Google Scholar
• Moulin-Romsee G, Hindié E, Cuenca X, . 18F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 2010;37:1095–1105.
   PubMed Web of Science ®Google Scholar
• Weiler-Sagie M, Bushelev O, Epelbaum R, . 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010;51: 25–30.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Angelopoulou MK, Constantinou N, . Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood 2005;105:1875–1880.
   PubMed Web of Science ®Google Scholar
• Bairey O, Shpilberg O. Is bone marrow biopsy obligatory in all patients with non-Hodgkins lymphoma? Acta Haematol 2007;118: 61–64.
   PubMed Web of Science ®Google Scholar